Company Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis.
It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.
The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2011 |
| IPO Date | May 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Jennifer Good |
Contact Details
Address: 195 Church Street, 16th Floor New Haven, Connecticut 06510 United States | |
| Phone | 203 304 2499 |
| Website | trevitherapeutics.com |
Stock Details
| Ticker Symbol | TRVI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001563880 |
| CUSIP Number | 89532M101 |
| ISIN Number | US89532M1018 |
| Employer ID | 45-0834299 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jennifer L. Good | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Thomas R. Sciascia M.D. | Co-Founder and Chief Scientific Officer |
| Dr. James V. Cassella Ph.D. | Chief Development Officer |
| Lisa Delfini | Chief Financial Officer |
| Christopher Galletta | Controller and Chief Accounting Officer |
| Katie McManus | Communications Manager |
| Farrell Simon Pharm.D. | Chief Commercial Officer |
| Danine Summers | Vice President of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 4, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 8-K | Current Report |